Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-001 in Severe COVID-19 Pneumonia
NCT04522986Phase 1Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-001 in COVID-19 pneumonia, sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Adverse Event at 12 weeks. Started Aug 2020; status: completed.
02
Drugs
ADR-001
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04522986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522986.